Maryland Patent of the Month – April 2025
Theriva Biologics, Inc. has earned U.S. Patent No. 12,274,740, titled “Microbiome Protection from Oral Antibiotics.” This new invention aims to protect the gut during antibiotic use—offering a way to prevent common side effects without weakening the medicine’s power.
How It Works
The patented product is an oral capsule that contains beta-lactamase enzymes. These enzymes break down specific antibiotics only in the intestines. Thanks to a special coating, the capsule releases its contents at just the right spot—leaving the rest of the body unaffected.
Why It Matters
Antibiotics often disturb the gut’s natural balance, leading to issues like diarrhea or infections. This product works alongside antibiotics, shielding good bacteria from harm. As a result, patients can heal faster and avoid added complications.
Real-World Impact
By protecting the microbiome, this solution could improve treatment results and lower hospital costs. It also highlights a growing focus on patient-centered therapies that work in harmony with the body. Theriva’s patent may open doors for more advanced care in the future.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
